IQVIA Holdings emerges as the more attractive value pick over Penumbra in the Medical - Instruments sector, according to Zacks Investment Research. IQVIA holds a Zacks Rank of #2 (Buy) with an improving earnings outlook, while Penumbra carries a Zacks Rank of #5 (Strong Sell). Valuation metrics further support the case: IQVIA has a forward P/E of 16.21, a PEG ratio of 1.61, and a P/B of 5.55, earning a Value grade of B. In contrast, Penumbra shows a forward P/E of 63.35, a PEG ratio of 1.97, and a P/B of 8.51, resulting in a Value grade of F.
IQVIA Holdings IncZacks ranks IQVIA as Buy with improving earnings outlook and favorable valuation metrics.
Penumbra IncZacks ranks Penumbra as Strong Sell with poor valuation metrics (high P/E, PEG, P/B).